EDIUNET Free equity investment tool of Japanese companies

Companies Cart
@
Credit Rating Analysis
Annual
First quarter
Second quarter
Third quarter
Sponsored Link
Related Company
@ NIHON KAGAKU SANGYO
@ Daito Pharmaceutical Co .
@ SANYO CHEMICAL INDUSTRIES
@ ステラケミファ
@ MUTO SEIKO CO.
@ あすか製薬
@ HAGIHARA INDUSTRIES
@ KUREHA
@ ZERIA PHARMACEUTICAL
@ Riken Vitamin
@ MATSUMOTO YUSHI-SEIYAKU
@ AGRO-KANESHO.
@ SEIKAGAKU 
@ Ube Industries
@ MITSUBISHI PLASTICS
EDIUNET Related Ranking
EDIUNET
EDIUNET Credit Rating
EDIUNET Industry Avg
EDIUNET Prefectures
Yuho! Industry
EDIUNET Rating News
Prev « 2024-03 » Next
Mon Tue Wed Thu Fri Sat Sun
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
[Update list]
1/28 Retail Trade (CAWACHI:A etc...
1/27 Banks (The Awa Bank:BBB→A)
1/23 Chemicals (Milbon:AA→AAA)
1/21 Glass & Ceramics Products (..
1/21 Machinery (TSUDAKOMA:C)
1/21 Other Services (Netindex.:CC)
1/20 Other Products (Kurogane Kos..
1/20 Wholesale Trade (リーバイ・..
1/20 Other Services (川崎地質:BB→..
1/17 Chemicals (Kawaguchi Chemica..
 RSS
 Company RSS
 Daily RSS
Sponsored Link
Recently Download Chart
Nissan Motor
graph
日本セラミック
graph
日本セラミック
graph
日本セラミック
graph
日本セラミック
graph

Credit Rating Analysis: TAIKO PHARMACEUTICAL (Annual )

The details of credit rating (bankruptcy risk) can be checked. A credit rating in nine stages (AAA-C).

【Analysis Menu】 @Outline @Statement @Rating @Indicator @Download

Sponsored Link

Credit Rating (Bankruptcy Risk): TAIKO PHARMACEUTICAL (Annual ) Consolidated | Non-Consolidated

Date Credit Rating Comment Sales Current Profit Net Income
2013-03-31  A  Credit is high, but affected by biz environs. ¥ 7 B
11.37%
¥ 1 B
117.02%
¥ 1 B
115.14%

Financial Timeline

Date  2012-12-31 
(Third quarter )
 2013-03-31 
(Annual )
 2013-06-30 
(First quarter )
 2013-09-30 
(Second quarter )
Credit Rating AAAA
Total Assets
¥ 12 B
¥ 13 B
¥ 13 B
¥ 13 B
Net Assets
¥ 9 B
¥ 9 B
¥ 9 B
¥ 10 B

Financial Statement Risk Analysis: TAIKO PHARMACEUTICAL (Annual ) (Consolidated )

Special note
Cash(¥ 5 B) is more than the total liabilities(¥ 3 B). It is a very steady fiscal base!
[Date: 2013-03-31]  Danger : Warning : Caution : Good
Financing Risk (*Issuance of new shares)
Financial Cash Flow (¥ -451 M) is a minus, Issuance of new shares (¥ 45 M) is plus. Because a possibility of having appropriated the capital-increase fund for repayment of borrowed money is high , there is a possibility that the financing is extremely severe.
Financing Risk (*Issuance of new shares)
Investment Cash Flow (¥ 13 M) is a plus, Issuance of new shares (¥ 45 M) is plus. Because it is thought that the circulating fund is gained by sale and new issue of stocks of stock property , there is a possibility that the financing is severe.
Dividend
Under the situation of Net Income (¥ 1 B) & Operating Cash Flow (¥ 1 B) , Dividend (¥ -194 M) is paid.
[Date: 2012-03-31]  Danger : Warning : Caution : Good
Financing Risk (*Issuance of new shares)
Financial Cash Flow (¥ -24 M) is a minus, Issuance of new shares (¥ 36 M) is plus. Because a possibility of having appropriated the capital-increase fund for repayment of borrowed money is high , there is a possibility that the financing is extremely severe.
Financing Good (*Operating Cash Flow is plus )
Investment Cash Flow (¥ -117 M) & Financial Cash Flow (¥ -24 M) is a minus, Operating Cash Flow (¥ 533 M) is a plus,
Dividend
Under the situation of Net Income (¥ 482 M) & Operating Cash Flow (¥ 533 M) , Dividend (¥ -64 M) is paid.
[Date: 2011-03-31]  Danger : Warning : Caution : Good
Management Risk (*Net Income & Operating Cash Flow is minus or 0 )
Net Income(¥ -2 B) & Operating Cash Flow (¥ -1 B) is minus or 0, so , there is a possibility that the management situation is very severe.
Financing Risk (*Operating Cash Flow is minus or 0 &Net Income & Sales is sharp decrease )
As compared with the first term of Sales (¥ 4 B) , Sales (¥ 8 B) is less than 80%, and As compared with the first term of Net Income (¥ 1 B) , Net Income (¥ -2 B) is less than 10%, Operating Cash Flow (¥ -1 B) is compensated for Investment Cash Flow (¥ 828 M) etc. , there is a possibility that the financing is extremely severe.
Financing Risk (*Issuance of new shares)
Financial Cash Flow (¥ -61 M) is a minus, Issuance of new shares (¥ 81 M) is plus. Because a possibility of having appropriated the capital-increase fund for repayment of borrowed money is high , there is a possibility that the financing is extremely severe.
Management Risk (*Sales is decrease )
Sales (¥ 4 B) is first term Sales (¥ 8 B) less , there is a possibility that the management situation has stagnated and deteriorated
Management Risk (*Net Income is decrease )
Net Income (¥ -2 B) is first term Net Income (¥ 1 B) less , there is a possibility that the management situation has stagnated and deteriorated
Management Risk (*Net Profit Margin is decrease )
Net Profit Margin (-48.24%) is first term Net Profit Margin (18.66%) less , there is a possibility that the profitability has deteriorated.
Financing Risk (*Issuance of new shares)
Investment Cash Flow (¥ 828 M) is a plus, Issuance of new shares (¥ 81 M) is plus. Because it is thought that the circulating fund is gained by sale and new issue of stocks of stock property , there is a possibility that the financing is severe.
Dividend Risk
Under the situation of Net Income (¥ -2 B) & Operating Cash Flow (¥ -1 B), Dividend (¥ -127 M) is paid.
Financing Risk (*Sale of stock property)
Operating Cash Flow (¥ -1 B) is minus, Investment Cash Flow (¥ 828 M) is plus. Because the main occupation was dull, stock property may have been sold off.
Non-performing asset Risk (*Accounts Receivable and Inventory, etc. confirmed content)
Other Current Assets first term ratio (¥ -415 M) is Sales first term ratio (¥ -4 B) more , there is a possibility that the non-performing asset was increased.
[Date: 2010-03-31]  Danger : Warning : Caution : Good
Financing Good (*Operating Cash Flow is plus )
Investment Cash Flow (¥ -110 M) & Financial Cash Flow (¥ -33 M) is a minus, Operating Cash Flow (¥ 1 B) is a plus,
Dividend
Under the situation of Net Income (¥ 1 B) & Operating Cash Flow (¥ 1 B) , Dividend (¥ -21 M) is paid.
[Date: 2009-03-31]  Danger : Warning : Caution : Good
Financing Good (*Operating Cash Flow is plus )
Investment Cash Flow (¥ -564 M) & Financial Cash Flow (¥ -13 M) is a minus, Operating Cash Flow (¥ 1 B) is a plus,
Dividend
Under the situation of Net Income (¥ 470 M) & Operating Cash Flow (¥ 1 B) , Dividend (¥ -10 M) is paid.

Ticker Market Industry Month report Rating
@ TAIKO PHARMACEUTICAL 4574 TSE 1st Chemicals 3 Annual A

Related Company

@ SANYO CHEMICAL INDUSTRIES (Sales ¥ 142 B)
@ OSAKA ORGANIC CHEMICAL INDUSTRY (Sales ¥ 22 B)
@ MATSUMOTO YUSHI-SEIYAKU (Sales ¥ 27 B)
@ KUREHA (Sales ¥ 130 B)
@ Riken Vitamin (Sales ¥ 77 B)
@ あすか製薬 (Sales ¥ 40 B)
@ TERAOKA SEISAKUSHO (Sales ¥ 19 B)
@ 扶桑化学工業 (Sales ¥ 27 B)
@ FUJIKURA KASEI (Sales ¥ 53 B)
@ SEIKAGAKU  (Sales ¥ 26 B)
@ TOSOH (Sales ¥ 668 B)
@ TAIKO PHARMACEUTICAL (Sales ¥ 7 B)
@ 日本曹達 (Sales ¥ 127 B)
Sponsored Link


関連する株式投資情報

EDIUNET Caution

*Financial data might be different from the actual one. Please confirm the original, and read Caution.

*This site has obtained the information from the FSA's EDINET, Tokyo Stock Exchange's TDnet and Pay statistical data services, Fukuoka stock Exchange's Stock market capitalization, Center for Spatial Information Science's CSV Geocoding Service. The copyright of the information belongs to each corporation etc. .

▲ Go to the top ▲

  1. Guide
  2. Mobile
  3. Tablet
  4. Japanese
`EDIUNET` Copyright©2006-2024 `MAバンク` (0.091 sec.)